MarginsXMarginsX
Home › Markets › Health Care › KURA

Kura Oncology Inc. (KURA)

KURA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$7.09
-8.75% on the day
Market cap
$651.4M
Small cap
Revenue · 2025
$67.5M
+25.2% on 2024
Net income · 2025
-$278.7M
-412.9% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1422143/000119312526092567/0001193125-26-092567-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerKURA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001422143
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$67.5M
Net income-$278.7M
Operating income-$303.6M
Net margin-412.9%
Operating margin-449.9%
Revenue growth+25.2%
Cash$149.1M
Total assets$738.4M
P/E (computed)Net income was not positive
P/S (computed)9.7×

Warning signs

Cash runway
8.1 months
$57.9M cash at September 30, 2026
Share count, 1 year
+5.6%
2025-10-31 to 2026-11-06 · +23.7% over 3 years
Going-concern doubt
No
10-Q filed November 10, 2026
Insider net buying, 12 months
-$1.5M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-10
Cash and burn$57.9M cash; operating cash flow -$21.4M a quarter.Report 2026-09-30
Shares outstanding91,878,694 (2026-11-06); 87,017,518 a year earlier; 74,272,111 three years earlier.Cover page 2026-11-06
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-11-10
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Diego, California, United StatesPCAOB Form AP 2026-03-18
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $2.4M, sold $3.8M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$22.8M-$70.2M-$54.4M$57.9M$9.8M$79.3M10-Q 2026-11-10
Q2 2026
2026-06-30
$20.9M-$68.3M-$62.5M$70.2M$9.8M$77.2M10-Q 2026-08-12
Q1 2026
2026-03-31
$18.3M-$73.3M-$85.9M$39.1M$9.7M$71.6M10-Q 2026-05-12
Q4 2025
2025-12-31
$17.3M-$81.0M$117.3M$149.1M$9.7M$67.5M10-K 2026-03-05
Q3 2025
2025-09-30
$20.8M-$74.1M-$80.6M$95.3M$9.7MNeeds four quarters10-Q 2026-11-10
Q2 2025
2025-06-30
$15.3M-$66.1M-$28.8M$81.9M$9.6MNeeds four quarters10-Q 2026-08-12
Q1 2025
2025-03-31
$14.1M-$57.4M-$71.9M$51.3M$9.6MNeeds four quarters10-Q 2026-05-12
Q4 2024
2024-12-31
Not filed-$19.2M$269.1M$224.5M$9.5M$53.9M10-K 2026-03-05

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2026-11-10
Latest annual report10-K2026-03-05
Latest quarterly / interim10-Q2026-11-10
Latest current report8-K2026-11-10
Latest proxyDEFA14A2026-05-26

Source: SEC EDGAR submissions feed, 810 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+6.9%
1 month-21.0%
3 months-23.0%
Year to date-25.2%
1 year-27.2%
From 52-week high-42.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
BCAXBicara Therapeutics Inc.$9.75-2.69%$647.3M
ANLAdlai Nortye Group Ltd.$10.03-5.47%$645.9M
NVCTNuvectis Pharma Inc.$19.11-5.58%$657.2M
OLMAOlema Oncology Inc.$7.36-2.65%$644.8M
ALMSAlumis Inc.$5.14-8.21%$667.3M
DSGNDesign Therapeutics Inc.$9.92-5.25%$635.2M
JANXJanux Therapeutics Inc.$10.92-3.96%$668.1M
IMMXImmix Biopharma Inc.$7.48-4.59%$626.9M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier